Apellis Pharmaceuticals, Inc. (APLS) Reports Q4 Loss, Lags Revenue Estimates

分组1 - Apellis Pharmaceuticals, Inc. reported a quarterly loss of $0.73 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.66, but an improvement from a loss of $1.50 per share a year ago [1] - The company posted revenues of $146.38 million for the quarter, missing the Zacks Consensus Estimate by 0.03%, but significantly up from $22.66 million year-over-year [1] - Over the last four quarters, Apellis has surpassed consensus revenue estimates three times, while it has only surpassed EPS estimates once [1] 分组2 - The stock has gained approximately 19.8% since the beginning of the year, outperforming the S&P 500's gain of 6.3% [2] - The current consensus EPS estimate for the upcoming quarter is -$0.46 on revenues of $158.9 million, and for the current fiscal year, it is -$1.10 on revenues of $784.78 million [4] - The Medical - Biomedical and Genetics industry, to which Apellis belongs, is currently ranked in the top 32% of over 250 Zacks industries, indicating a favorable outlook for the sector [5]